Feedback Share Discussion Threads

[blueball] 06/11/2015 08:28

Careful the results are not good.

[norbert colon] 04/11/2015 12:00

I believe the AGM is soon to be announced - I hope that a number of investors attend. I certainly intend to.

[lr2] 03/11/2015 18:43

Feedback PLC – ICENI Centre & ISLCRS study to investigate whether textural features of rectal cancer on Magnetic Resonance can predict long term survival

Magnetic resonance based texture parameters as potential imaging biomarkers for predicting long term survival in locally advanced rectal cancer patients.

[andya99] 03/11/2015 18:14

hxxp://www.pharmatimes.com/Article/15-11-02/New_initiative_to_boost_UK_pathology_research.aspx


"Last month Cancer Research UK awarded Queens University Belfast £3.9 million to develop new pathology and image analysis techniques for solid tumours.

This includes research to improve cancer diagnosis through tissue imaging, biomarker discovery and clinical trials, and the cash will also underpin the next generation of scientists with a Clinical Fellowship programme in molecular pathology, the charity said."

[zeuss1] 26/10/2015 07:58

The results of this study seem to have been missed here. Although this took place in July it provides yet more anecdotal evidence of the growing importance attached to texture analysis, of which Feedback (TexRAD) seems to have cornered the market.

- On July 20th 2015, Feedback plc announced the successful completion of a large evaluation of TexRAD CT texture analysis (CTTA) as a pre-therapy imaging biomarker in 241 metastatic renal (kidney) cell cancer (m-RCC) patients treated with anti-angiogenic therapy (AAT – drugs that block cancer blood-vessel growth).

The research study was led by Dr. Andrew Smith (Associate Professor in Radiology and Director of Radiology Research) along with colleagues from the University of Mississippi Medical Center, Jackson, Mississippi, USA (UMMC).

Specifically the results from this large study demonstrated that TexRAD texture analysis on conventional CT imaging acquired before m-RCC patients underwent AAT was a very strong predictor of overall survival at 2 years. Dr. Smith and colleagues further demonstrated that in a multivariate model comprising of known clinical biomarkers in this cancer population, TexRAD CTTA additionally demonstrated to be a strongly independent predictor of overall survival. The authors have developed a “new prognostic risk index” comprising of TexRAD CTTA and other known clinical factors which has demonstrated superior accuracy in predicting patient survival and classified patients into low, medium and high-risk groups with strong statistical significance. Dr. Smith and colleagues also concluded that pre-therapy TexRAD CTTA is a significant prognostic marker in patients with m-RCC treated with AAT.

On October 7th-11th, 2015 Dr Andrew Smith presented the data from this large patient study (n=241) on the use of TexRAD texture analysis on CT scans in predicting survival in secondary kidney cancer patients treated with anti-vascular drugs.

The presentation at the Society of Computed Body Tomography and Magnetic Resonance (SCBT-MR) Conference was awarded the Best Junior Researcher Presentation. Slides here hxxp://www.branduk.net/feedback-plc-presentation-of-study-results/

[blueball] 12/10/2015 08:32

I would be happy with 5p by xmas.

[blueball] 11/10/2015 20:35

Afraid its last weeks news.

[andya99] 11/10/2015 17:52

Zak Mir's Bull Call Of The Day No.1:Feedback: 5p In View After Latest Gap Higher

hxxp://www.shareprophets.com/views/15572/zak-mir-s-bull-call-of-the-day-no1feedback-5p-in-view-after-latest-gap-higher

[blueball] 09/10/2015 20:15

Will have a listen over the weekend.

[britstox] 09/10/2015 17:10

What a great pod cast

[lr2] 09/10/2015 16:08

Thanks for posting Ken. Feedback chat starts around 24:30. Have re-posted link as yours has been modified by Advfn.

[kenwrong] 09/10/2015 15:56

Just caught the latest interview with Dr Ganeshan after the announcements on this week. Well worth a listen. hxxps://audioboom.com/boos/3672264-318-teathers-financial-plc-and-feedback-plc

[zeuss1] 09/10/2015 09:22

It is gratifying that Feedback have clarified strategy and removed the FDA approval will they / won't they uncertainties. The medical profession are now waking up to TexRAD's potential - Stone Checker, Prostate Checker and potential in the area of lung cancer as highlighted by the NHS 'alert' are most likely just the start of a series of multiple applications for TexRAD going forward. Plus there is Cadran, the almost forgotten side of the business. Image archiving used by hospitals up and down the country, including Addenbrookes. No doubt we can expect some developments here at some point.

[the stigologist] 08/10/2015 16:35

When's the placing Frauddy ?

[the stigologist] 08/10/2015 15:18

Nasty double top on that chart now.


The Grand Old Duke of York...

[the stigologist] 08/10/2015 08:20

Not really a lot to audit here is there ?

Revenue for the six month period was £229,000 (2013: non trading) and the loss after tax was £219,000. (2013: loss of £471,000). The loss before interest, tax and amortisation was £138,000 (2013: Loss £471,000). The cash balance at 30 November 2014 was £268,000, (2013: £696,000) which was after the payment of certain overdue creditors totalling £189,000 owed by CCI.

[the stigologist] 08/10/2015 08:19

When's the placing Frauddy ?

[the stigologist] 08/10/2015 08:16

When's the placing Frauddy ?

[blueball] 08/10/2015 08:06

Added a few more @3.37p.

[the stigologist] 08/10/2015 07:41

Trying to make a virtue of necessity

Obviously they need funding and a placing is imminent and in that process realised the amount they need to raise to see them through to end of FDA process is too large

Very clever from ramping merchant Frauddy, let's see if the market sees through his games

[someuwin] 08/10/2015 07:35

So they expect the prostate cancer and kidney stones joint ventures to be generating significant revenues and are confident of signing more such JVs and collaborations with other partners.

Sounds like a more focussed approach and a quicker route to commercialisation.

Good that we don't have the never-ending wait for FDA approval hanging over us.

[photon] 08/10/2015 07:35

Just a personal take on the RNS, as someone who works in medical: they thought they would need FDA approval to get recognition and traction, but now it's clear they don't - they have recognition and traction anyway. And the business model is now moving to one that will look much more attractive to investors, because their burgeoning success makes it possible for them to do so.

[someuwin] 08/10/2015 07:08

RNS


RNS Number : 5703B

Feedback PLC

08 October 2015




Feedback plc

("Feedback" or the "Company")

Strategy Update

Feedback plc (AIM: FDBK), the medical imaging software company, is pleased to announce an update on its corporate strategy. Feedback has recently announced two joint ventures where its TexRAD texture analysis software is to be incorporated into developing new products designed specifically for the assessment and management of patients with prostate cancer and kidney stones.

In the light of these exciting developments the Board has re-evaluated the Company's strategy for seeking FDA approval for TexRAD as a stand-alone software application.

In the Company's Admission document and in previous results announcements the Company indicated it was preparing to make a 510(k) submission for TexRAD to be used as an analytical tool for measuring texture in CT scans. The Company now recognises that there are significant commercial opportunities available to Feedback if TexRAD is used in conjunction with other imaging biomarkers to create integrated products for specific clinical applications. The Board expects these types of products to be marketed much more effectively to clinicians compared with a general software application. As part of the updated strategy the Company is also considering prioritising CE marking in order to accelerate development of commercial products for the European markets.

As a consequence of this new focus, FDA approval for TexRAD is no longer regarded as one of the Company's principal corporate objectives.

Feedback has sold research versions of TexRAD software to many of the world's leading oncology research centres. In conjunction with this, pioneering research is being undertaken in these centres to evaluate how texture analysis can be introduced into radiology workflow to assist clinicians in the assessment and patient management of various different types of cancer. Feedback is now at the stage where the publication of research findings is likely to have a significant effect on determining where the Company should be concentrating its efforts.

As a result of the changes highlighted above the Company has concluded that it no longer has a compelling strategic need to continue the sale of research versions of TexRAD to a broad market and intends to restrict further sales of the research versions of TexRAD to a limited number of new customers.

The Company's future strategy is expected to involve the formation of more joint ventures and collaborations where Feedback's valuable intellectual property can be combined with the specialist skills and intellectual property of other companies and research institutions. By adopting this approach the Company is expected to generate licensing and royalty revenue streams and a residual equity participation in these joint ventures.

The Company's audited results for the financial year ended 31 May 2015 are expected to be announced by 31 October 2015.